false
Catalog
2023 World Conference on Lung Cancer (Posters)
P2.01. An Update on the CONCORDE study: A Phase Ib ...
P2.01. An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC - PDF(Abstract)
Back to course
Pdf Summary
The CONCORDE study is a phase Ib platform study that aims to assess novel agents in combination with conventional radiotherapy (RT) in non-small cell lung cancer (NSCLC) patients. The study utilizes an adaptive Bayesian model-based approach to dose escalation. Participants receive RT and are allocated to one of five study arms, with three of the arms also receiving consolidation durvalumab. The primary objective is to assess safety and determine the recommended phase II dose of each combination. As of March 2023, three arms of the study are open to recruitment across nine centers. Out of the 35 participants randomized, no dose limiting toxicities have been observed in the DNA damage response inhibitors (DDRi) arms. The trial continues to recruit, with one arm submitted and scheduled to open in May 2023. A parallel translational program is also in development to identify biomarkers of treatment response, toxicity, and the impact on the immune system. Biomarkers of interest include plasma toxicity markers, immune cell profiling, radiomics, and ctDNA. The study is a collaboration between the University of Leeds, CRUK, and AstraZeneca, and aims to provide insights into the use of novel therapies in combination with radiotherapy for NSCLC patients.
Asset Subtitle
Ashley Horne
Meta Tag
Speaker
Ashley Horne
Topic
Local-Regional NSCLC: Novel Therapies & Trials
Keywords
CONCORDE study
phase Ib platform study
novel agents
conventional radiotherapy
non-small cell lung cancer
adaptive Bayesian model-based approach
dose escalation
consolidation durvalumab
safety assessment
recommended phase II dose
×
Please select your language
1
English